Violeta Iric-Cupic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Violeta Iric-Cupic has a total of 681 co-authors. Here are the top co-authors by number of shared publications:
- Rada Vucic
Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica Street 69, 34000 Kragujevac, Serbia
8 shared publications - Vladimir Zdravkovic
Clinical center Kragujevac Cardiology Clinic
7 shared publications - Goran Davidovic
Clinic for Cardiology, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia
6 shared publications Ivan Simic
Clinic for Cardiology, Clinical Center Kragujevac, Kragujevac, Serbia
4 shared publications- Vladimir Ignjatovic
Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
4 shared publications G. Davidovic
3 shared publications
Latest Publications
- 1 January 2022
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Galenika Medical Journal
- Vol. 1 (3) , 49-59
A step further in uncontrolled hyperlipidemia
In the genesis of the origin and development of cardiovascular diseases and the ischemic heart disease, the process of atherosclerosis plays a key role. Since hyperlipidemia is a potentially variable risk factor for the development of atherosclerosis, its treatment is a basic clinical imperative for the prevention of cardiovascular disease. Treatment of hyperlipoproteinemia aims to slow the development of atherosclerosis and reduce the frequency of its consequences and involves the use of statins, ezetimibe, fibrates, nicotinic acid and ion exchangers. A monotherapeutic approach is recommended, when the degree of lipid metabolic disorder is such that it can be estimated that monotherapy will be sufficient to achieve the desired values of lipoprotein profile parameters. The advantages of the monotherapeutic approach are shown by the latest generation statins, atorvastatin and rosuvastatin,which in high doses exhibit a highly intense hypolipidemic effect, and have proven pleiotropic effects. When monotherapy is not sufficient, it is necessary to conduct combination therapy with ezetimibe to potentiate the hypocholesterolemic effect, or fibrate to potentiate the reduction in triglycerides, but may be combined with other available hypolipidemics. This work should facilitate decision-making on the choice of therapeutic approach, in accordance with current guidelines for the treatment of hyperlipidemia, according to the estimated target values of LDL cholesterol. Target LDL values are determined depending on the assessed cardiovascular risk, according to the SCORE table (for persons without comorbidities, to assess the probability of fatal cardiovascular events in a ten-year period, expressed as a percentage), as well as risk assessments for the population diagnosed with cardiovascular disease, diabetes, or renal failure. The target value of LDL, for people with an estimated low risk is < 3 mmol / l, high risk < 2.6 mmol / l, very high < 1.8 mmol / l. The choice of treatment for hyperlipidemia depends on the estimated cardiovascular risk, and the estimated desired LDL values. High-intensity statins are preferred in the monotherapy approach, and if this approach is not sufficient to achieve the desired LDL values, or there is statin intolerance, combination therapy should be considered.
- 1 January 2022
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Galenika Medical Journal
- Vol. 1 (3) , 49-59
A step further in uncontrolled hyperlipidemia
In the genesis of the origin and development of cardiovascular diseases and the ischemic heart disease, the process of atherosclerosis plays a key role. Since hyperlipidemia is a potentially variable risk factor for the development of atherosclerosis, its treatment is a basic clinical imperative for the prevention of cardiovascular disease. Treatment of hyperlipoproteinemia aims to slow the development of atherosclerosis and reduce the frequency of its consequences and involves the use of statins, ezetimibe, fibrates, nicotinic acid and ion exchangers. A monotherapeutic approach is recommended, when the degree of lipid metabolic disorder is such that it can be estimated that monotherapy will be sufficient to achieve the desired values of lipoprotein profile parameters. The advantages of the monotherapeutic approach are shown by the latest generation statins, atorvastatin and rosuvastatin,which in high doses exhibit a highly intense hypolipidemic effect, and have proven pleiotropic effects. When monotherapy is not sufficient, it is necessary to conduct combination therapy with ezetimibe to potentiate the hypocholesterolemic effect, or fibrate to potentiate the reduction in triglycerides, but may be combined with other available hypolipidemics. This work should facilitate decision-making on the choice of therapeutic approach, in accordance with current guidelines for the treatment of hyperlipidemia, according to the estimated target values of LDL cholesterol. Target LDL values are determined depending on the assessed cardiovascular risk, according to the SCORE table (for persons without comorbidities, to assess the probability of fatal cardiovascular events in a ten-year period, expressed as a percentage), as well as risk assessments for the population diagnosed with cardiovascular disease, diabetes, or renal failure. The target value of LDL, for people with an estimated low risk is < 3 mmol / l, high risk < 2.6 mmol / l, very high < 1.8 mmol / l. The choice of treatment for hyperlipidemia depends on the estimated cardiovascular risk, and the estimated desired LDL values. High-intensity statins are preferred in the monotherapy approach, and if this approach is not sufficient to achieve the desired LDL values, or there is statin intolerance, combination therapy should be considered.
- Open Access
- 20 May 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 364 (6) , 758-765
Effect and significance of hyperlipoproteinemia on stent thrombosis in patients with implanted drug-eluting stents: The 5-year follow up study
- 20 May 2021
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 364 (6) , 758-765
Open AccessEffect and significance of hyperlipoproteinemia on stent thrombosis in patients with implanted drug-eluting stents: The 5-year follow up study
- Open Access
- 22 February 2020
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
Hypertensive Crisis in Patients with Acute Intermittent Porphyria
- 22 February 2020
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
Open AccessHypertensive Crisis in Patients with Acute Intermittent Porphyria
- 1 June 2018
- Published by Elsevier in JACC: Heart Failure
- Vol. 6 (6) , 452-462
Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
- 1 June 2018
- Published by Elsevier in JACC: Heart Failure
- Vol. 6 (6) , 452-462
Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
- Open Access
- 1 June 2016
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
- Vol. 17 (2) , 93-98
Correlation between Timi Risk Score and Clinical Outcome in Patients with Unstable Angina Pectoris
Given Taking that the TIMI score is a major predictor of MACE, this study aimed to determine the value of the TIMI risk score in predicting poor outcomes (death, myocardial infarction, recurrent pain) in patients presenting with unstable angina pectoris in short-term observation. A total of 107 patients with APns were examined at the Clinical Centre Kragujevac and were included in the investigation. The TIMI score was determined on the first day of hospitalization. During hospitalization, the following factors were also observed: troponin, ECG evolution, further therapy (pharmacologic therapy and/or emergency PCI or CABG), age, hypertension and hyperlipidaemia. The low-risk group (TIMI 0 - 2) included 30.8% of patients, whereas 47.6% of patients were in the intermediate-risk group (TIMI 3 - 4), and 21.5% of patients were in the high-risk group (TIMI 5 - 7). Good outcomes (without adverse event) and poor outcomes (death, myocardial infarction, and recurring chest pain) were dependent on the TIMI risk score. The increase in TIMI risk score per one unit increased the risk of a poor outcome by 54%. Troponin and TIMI risk score were positively correlated. Our results suggest that the TIMI risk score may be a reliable predictor of a poor outcome (MACE) during the short-term observation of patients with APns. Moreover, patients identified as high-risk benefit from early invasive PCI, enoxaparin and Gp IIb/IIIa inhibitors. Th us, routine use of the TIMI risk score at admission may reduce the number of patients not recognized as high-risk.
- 1 June 2016
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
- Vol. 17 (2) , 93-98
Open AccessCorrelation between Timi Risk Score and Clinical Outcome in Patients with Unstable Angina Pectoris
Given Taking that the TIMI score is a major predictor of MACE, this study aimed to determine the value of the TIMI risk score in predicting poor outcomes (death, myocardial infarction, recurrent pain) in patients presenting with unstable angina pectoris in short-term observation. A total of 107 patients with APns were examined at the Clinical Centre Kragujevac and were included in the investigation. The TIMI score was determined on the first day of hospitalization. During hospitalization, the following factors were also observed: troponin, ECG evolution, further therapy (pharmacologic therapy and/or emergency PCI or CABG), age, hypertension and hyperlipidaemia. The low-risk group (TIMI 0 - 2) included 30.8% of patients, whereas 47.6% of patients were in the intermediate-risk group (TIMI 3 - 4), and 21.5% of patients were in the high-risk group (TIMI 5 - 7). Good outcomes (without adverse event) and poor outcomes (death, myocardial infarction, and recurring chest pain) were dependent on the TIMI risk score. The increase in TIMI risk score per one unit increased the risk of a poor outcome by 54%. Troponin and TIMI risk score were positively correlated. Our results suggest that the TIMI risk score may be a reliable predictor of a poor outcome (MACE) during the short-term observation of patients with APns. Moreover, patients identified as high-risk benefit from early invasive PCI, enoxaparin and Gp IIb/IIIa inhibitors. Th us, routine use of the TIMI risk score at admission may reduce the number of patients not recognized as high-risk.
- Open Access
- 1 May 2016
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 57 (3) , 181-184
Fulminant myocarditis as a primary manifestation of H1N1 infection: A first reported case from Serbia
- 1 May 2016
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 57 (3) , 181-184
Open AccessFulminant myocarditis as a primary manifestation of H1N1 infection: A first reported case from Serbia
- Open Access
- 13 April 2015
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 21 (1) , 44-52
Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy
The use of β-blockers in the treatment of patients with coronary heart disease is associated with a decrease in the frequency of angina pectoris and mortality of patients. Due to the severity of the disease and previous cardiovascular interventions, many patients with coronary artery disease (CAD) use dual antiplatelet therapy to achieve greater inhibition of platelet aggregation. The influence of β-blockers on platelet aggregation in patients using antiplatelet therapy is not well understood. To examine the effect of different β-blockers on platelet aggregation in patients on dual antiplatelet therapy. The study included 331 patients who were treated at the Department of Cardiology, Clinical Center Kragujevac during 2011. Patients were divided into 4 groups depending on the type of β-blockers that were used (bisoprolol, nebivolol, metoprolol, and carvedilol). Platelet aggregation was measured using the multiplate analyzer and expressed through the value of adenosine diphosphate (ADP) test (to assess the effect of clopidogrel), ASPI test (to assess the effect of acetyl salicylic acid), TRAP test (to assess baseline platelet aggregation), and the ratio of ADP/TRAP and ASPI/TRAP ASPI/TRAP (ASPI - aranchidonic acid induced aggregation, TRAP - thrombin receptor activating peptide) representing the degree of inhibition of platelet aggregation compared to the basal value. In consideration were taken the representation of demographic, clinical characteristics, laboratory parameters, and cardiovascular medications between the groups. Patients who used nebivolol had a significantly lower value of the ratio of ADP/TRAP (0.39 ± 0.30) compared to patients who used bisoprolol (0.48 ± 0.26; P = .038), and trend toward the lower values of ADP test (328.0 ± 197.3 vs 403.7 ± 213.2; P = .059), while there was no statistically significant difference in values of other laboratory parameters of platelet function between other groups. Patients with CAD on dual antiplatelet therapy who used nebivolol had significantly lower levels of residual ADP-induced platelet aggregation compared to baseline than patients who used bisoprolol.
- 13 April 2015
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 21 (1) , 44-52
Open AccessInfluence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy
The use of β-blockers in the treatment of patients with coronary heart disease is associated with a decrease in the frequency of angina pectoris and mortality of patients. Due to the severity of the disease and previous cardiovascular interventions, many patients with coronary artery disease (CAD) use dual antiplatelet therapy to achieve greater inhibition of platelet aggregation. The influence of β-blockers on platelet aggregation in patients using antiplatelet therapy is not well understood. To examine the effect of different β-blockers on platelet aggregation in patients on dual antiplatelet therapy. The study included 331 patients who were treated at the Department of Cardiology, Clinical Center Kragujevac during 2011. Patients were divided into 4 groups depending on the type of β-blockers that were used (bisoprolol, nebivolol, metoprolol, and carvedilol). Platelet aggregation was measured using the multiplate analyzer and expressed through the value of adenosine diphosphate (ADP) test (to assess the effect of clopidogrel), ASPI test (to assess the effect of acetyl salicylic acid), TRAP test (to assess baseline platelet aggregation), and the ratio of ADP/TRAP and ASPI/TRAP ASPI/TRAP (ASPI - aranchidonic acid induced aggregation, TRAP - thrombin receptor activating peptide) representing the degree of inhibition of platelet aggregation compared to the basal value. In consideration were taken the representation of demographic, clinical characteristics, laboratory parameters, and cardiovascular medications between the groups. Patients who used nebivolol had a significantly lower value of the ratio of ADP/TRAP (0.39 ± 0.30) compared to patients who used bisoprolol (0.48 ± 0.26; P = .038), and trend toward the lower values of ADP test (328.0 ± 197.3 vs 403.7 ± 213.2; P = .059), while there was no statistically significant difference in values of other laboratory parameters of platelet function between other groups. Patients with CAD on dual antiplatelet therapy who used nebivolol had significantly lower levels of residual ADP-induced platelet aggregation compared to baseline than patients who used bisoprolol.
- Open Access
- 1 January 2014
- Published by National Library of Serbia in Archives of Biological Sciences
- Vol. 66 (3) , 1075-1081
The subchronic effects of 3,4-methylendioxymethamphetamine on oxidative stress in rat brain
The aim of the present study was to evaluate the subchronic effects of 3,4-methylenedioxymethamphetamine on several oxidative stress markers: index of lipid peroxidation (ILP), superoxide dismutase (SOD) activity, superoxide radical (O2.-) levels, and reduced glutathione (GSH) levels in the frontal cortex, striatum and hippocampus of the rat. The study included 64 male Wistar rats (200-250g). The animals were treated per os with of 5, 10, or 20 mg/kg of 3,4-methylenedioxymethamphetamine (MDMA) every day for 15 days. The subchronic administration of MDMA resulted in an increase in ILP, SOD and O2.-, and a decrease in GSH, from which we conclude that oxidative stress was induced in rat brain.
- 1 January 2014
- Published by National Library of Serbia in Archives of Biological Sciences
- Vol. 66 (3) , 1075-1081
Open AccessThe subchronic effects of 3,4-methylendioxymethamphetamine on oxidative stress in rat brain
The aim of the present study was to evaluate the subchronic effects of 3,4-methylenedioxymethamphetamine on several oxidative stress markers: index of lipid peroxidation (ILP), superoxide dismutase (SOD) activity, superoxide radical (O2.-) levels, and reduced glutathione (GSH) levels in the frontal cortex, striatum and hippocampus of the rat. The study included 64 male Wistar rats (200-250g). The animals were treated per os with of 5, 10, or 20 mg/kg of 3,4-methylenedioxymethamphetamine (MDMA) every day for 15 days. The subchronic administration of MDMA resulted in an increase in ILP, SOD and O2.-, and a decrease in GSH, from which we conclude that oxidative stress was induced in rat brain.
- 15 September 2013
- Published by Scientific Foundation Spiroski (publications) in Macedonian Journal of Medical Sciences
- Vol. 6 (3)
„Obesity Paradox“ – Fiction or a Fact?
- 15 September 2013
- Published by Scientific Foundation Spiroski (publications) in Macedonian Journal of Medical Sciences
- Vol. 6 (3)
„Obesity Paradox“ – Fiction or a Fact?
- 15 September 2013
- Published by Scientific Foundation Spiroski (publications) in Macedonian Journal of Medical Sciences
- Vol. 6 (3)
Can Statins Help „Good Cholesterol“ to Become Even Better
- 15 September 2013
- Published by Scientific Foundation Spiroski (publications) in Macedonian Journal of Medical Sciences
- Vol. 6 (3)
Can Statins Help „Good Cholesterol“ to Become Even Better